246 related articles for article (PubMed ID: 22905983)
21. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
Rezaie AR
Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
[TBL] [Abstract][Full Text] [Related]
22. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin.
Nagase H; Enjyoji K; Minamiguchi K; Kitazato KT; Kitazato K; Saito H; Kato H
Blood; 1995 Mar; 85(6):1527-34. PubMed ID: 7888673
[TBL] [Abstract][Full Text] [Related]
23. Heparin sensitivity and resistance in the neonate: an explanation.
Vieira A; Berry L; Ofosu F; Andrew M
Thromb Res; 1991 Jul; 63(1):85-98. PubMed ID: 1658964
[TBL] [Abstract][Full Text] [Related]
24. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
[TBL] [Abstract][Full Text] [Related]
25. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
[TBL] [Abstract][Full Text] [Related]
26. Anticoagulant activity of a sulfated galactan: serpin-independent effect and specific interaction with factor Xa.
Glauser BF; Rezende RM; Melo FR; Pereira MS; Francischetti IM; Monteiro RQ; Rezaie AR; Mourão PA
Thromb Haemost; 2009 Dec; 102(6):1183-93. PubMed ID: 19967150
[TBL] [Abstract][Full Text] [Related]
27. Heparin blunts endotoxin-induced coagulation activation.
Pernerstorfer T; Hollenstein U; Hansen J; Knechtelsdorfer M; Stohlawetz P; Graninger W; Eichler HG; Speiser W; Jilma B
Circulation; 1999 Dec 21-28; 100(25):2485-90. PubMed ID: 10604885
[TBL] [Abstract][Full Text] [Related]
28. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif--the C-domain.
Al Dieri R; Wagenvoord R; van Dedem GW; Béguin S; Hemker HC
J Thromb Haemost; 2003 May; 1(5):907-14. PubMed ID: 12871355
[TBL] [Abstract][Full Text] [Related]
29. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
[TBL] [Abstract][Full Text] [Related]
30. Localization of an antithrombin exosite that promotes rapid inhibition of factors Xa and IXa dependent on heparin activation of the serpin.
Izaguirre G; Zhang W; Swanson R; Bedsted T; Olson ST
J Biol Chem; 2003 Dec; 278(51):51433-40. PubMed ID: 14532267
[TBL] [Abstract][Full Text] [Related]
31. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex.
Sheehan JP; Lan HC
Blood; 1998 Sep; 92(5):1617-25. PubMed ID: 9716589
[TBL] [Abstract][Full Text] [Related]
32. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.
Volovyk Z; Monroe DM; Qi Y; Becker R; Hoffman M
J Thromb Thrombolysis; 2009 Aug; 28(2):132-9. PubMed ID: 19543696
[TBL] [Abstract][Full Text] [Related]
33. Determination of the levels of unfractionated and low-molecular-weight heparins in plasma: their effect on thrombin-mediated feedback reactions in vivo. Preliminary results after subcutaneous injection.
Hemker HC; Béguin S; Bendetowicz AV; Wielders S
Haemostasis; 1991; 21(4):258-72. PubMed ID: 1665467
[TBL] [Abstract][Full Text] [Related]
34. Activation of blood coagulation at heparin-coated surfaces.
Blezer R; Fouache B; Willems GM; Lindhout T
J Biomed Mater Res; 1997 Oct; 37(1):108-13. PubMed ID: 9335355
[TBL] [Abstract][Full Text] [Related]
35. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides.
Wun TC
Blood; 1992 Jan; 79(2):430-8. PubMed ID: 1346095
[TBL] [Abstract][Full Text] [Related]
36. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
37. Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α.
Thomassen MC; Heinzmann AC; Herfs L; Hartmann R; Dockal M; Scheiflinger F; Hackeng TM; Rosing J
J Thromb Haemost; 2015 Jan; 13(1):92-100. PubMed ID: 25348176
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
[TBL] [Abstract][Full Text] [Related]
39. Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease.
Izaguirre G; Aguila S; Qi L; Swanson R; Roth R; Rezaie AR; Gettins PG; Olson ST
J Biol Chem; 2014 Dec; 289(49):34049-64. PubMed ID: 25331949
[TBL] [Abstract][Full Text] [Related]
40. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).
Eichinger S; Wolzt M; Schneider B; Nieszpaur-Los M; Heinrichs H; Lechner K; Eichler HG; Kyrle PA
Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):886-92. PubMed ID: 7600120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
